Literature DB >> 19302557

Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients.

Ghandi Damaj1, Frédérique Kuhnowski, Jean-Pierre Marolleau, Francis Bauters, Xavier Leleu, Ibrahim Yakoub-Agha.   

Abstract

Although the survival of patients with hairy cell leukemia (HCL) has been improved by the therapeutic introduction of interferon alpha and purine analogs, it is still worsened by complications such as severe infections. In this long-term study, we identified factors influencing patient outcomes in 73 patients with HCL. Median age at diagnosis was 53 yr and the gender ratio (M/F) was 2.3. At the time of HCL diagnosis, 60 patients (82%) were symptomatic and 22 of these had an infection. After a median follow-up of 13 yr, eight patients had died of secondary cancer (n = 2), HCL progression (n = 1) and age-related complications (n = 5). The 10-yr overall survival (OS), progression-free survival and relapse rates were 91 +/- 3%, 14 +/- 5% and 87 +/- 5%, respectively. In multivariate analyses, age >53 yr was the only factor adversely influencing OS and secondary cancer incidence, with adjusted hazard ratio (HR) of 9.30 (95%CI, 1.15-76.6; P = 0.037) and 2.80 (95%CI, 1.05-7.71; P = 0.04), respectively. Eleven patients developed severe infections. Absolute lymphocyte count (<1 x 10(9)/L) at diagnosis was the only factor influencing the occurrence of severe infections, with an adjusted HR of 4.01 (P = 0.007). Strikingly, we did not observe any significant correlation between neutrophil or monocyte counts and the incidence of infection. We confirmed long-term survival in HCL but found a high incidence of infection - even late in the course of the disease. The absolute lymphocyte count at diagnosis is a risk factor for the occurrence of severe infections. In addition to careful monitoring of infections, prompt initiation of anti-HCL treatment should be considered in patients with low lymphocyte counts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302557     DOI: 10.1111/j.1600-0609.2009.01259.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.

Authors:  Leslie A Andritsos; Neil Dunavin; Gerard Lozanski; Jeffrey A Jones; James S Blachly; David M Lucas; John C Byrd; Eric Kraut; Michael R Grever
Journal:  Haematologica       Date:  2014-10-31       Impact factor: 9.941

Review 2.  Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.

Authors:  Jérôme Paillassa; Elsa Maitre; Xavier Troussard
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

Review 3.  How I treat hairy cell leukemia.

Authors:  Michael R Grever
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

Review 4.  Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

Authors:  Michael Grever; Leslie Andritsos; Versha Banerji; Jacqueline C Barrientos; Seema Bhat; James S Blachly; Timothy Call; Matthew Cross; Claire Dearden; Judit Demeter; Sasha Dietrich; Brunangelo Falini; Francesco Forconi; Douglas E Gladstone; Alessandro Gozzetti; Sunil Iyengar; James B Johnston; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Francesco Lauria; Gerard Lozanski; Sameer A Parikh; Jae Park; Aaron Polliack; Farhad Ravandi; Tadeusz Robak; Kerry A Rogers; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine S Tam; Enrico Tiacci; Xavier Troussard; Clive Zent; Thorsten Zenz; Pier Luigi Zinzani; Bernhard Wörmann
Journal:  Leukemia       Date:  2021-05-04       Impact factor: 11.528

5.  Isolated Splenic Mycobacterial Disease: A Cause of Persistent Fever in a Hairy Cell Leukemia Patient.

Authors:  Vassilios Papadopoulos; Charalambos Kartsios; Anastassia Spyrou; Kostas Loukidis; Spyridon Miyakis; Stavroula Pervana; Charalambos Makridis; Anna Kioumi; Ioannis Korantzis
Journal:  Case Rep Gastroenterol       Date:  2010-09-11

6.  Hairy cell leukemia: short review, today's recommendations and outlook.

Authors:  V Maevis; U Mey; G Schmidt-Wolf; I G H Schmidt-Wolf
Journal:  Blood Cancer J       Date:  2014-02-14       Impact factor: 11.037

Review 7.  Epidemiology of infections in cancer patients.

Authors:  Teresa R Zembower
Journal:  Cancer Treat Res       Date:  2014

8.  Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.

Authors:  Jerome Paillassa; Edouard Cornet; Stephanie Noel; Cecile Tomowiak; Stephane Lepretre; Sandrine Vaudaux; Jehan Dupuis; Alain Devidas; Bertrand Joly; Charlotte Petitdidier-Lionnet; Stephanie Haiat; Clara Mariette; Catherine Thieblemont; Didier Decaudin; Patricia Validire-Charpy; Bernard Drenou; Jean-Claude Eisenmann; Mario Ojeda Uribe; Agnès Olivrie; Mohamed Touati; Olivier Lambotte; Olivier Hermine; Jean-Michel Karsenti; Pierre Feugier; Willy Vaillant; Jean Gutnecht; Eric Lippert; Fabienne Huysman; Kamel Ghomari; Marouane Boubaya; Vincent Levy; Jeremie Riou; Gandhi Damaj; Aline Tanguy-Schmidt; Mathilde Hunault-Berger; Xavier Troussard
Journal:  Blood Cancer J       Date:  2020-05-27       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.